S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:AMAG

AMAG Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$13.75
0.00 (0.00 %)
(As of 11/16/2020)
Add
Compare
Today's Range
$13.75
Now: $13.75
$13.75
50-Day Range
$13.69
MA: $13.74
$13.75
52-Week Range
$4.41
Now: $13.75
$13.80
VolumeN/A
Average Volume950,664 shs
Market Capitalization$477.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89
AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
AMAG Pharmaceuticals logo

MarketRank

Overall MarketRank

0.75 out of 5 stars

Medical Sector

1001st out of 1,556 stocks

Pharmaceutical Preparations Industry

465th out of 638 stocks

Analyst Opinion: 0.9Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMAG
CUSIP00163U10
Phone617-498-3300
Employees440

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$327.75 million
Book Value$7.37 per share

Profitability

Net Income$-466,460,000.00

Miscellaneous

Market Cap$477.47 million
Next Earnings Date3/3/2021 (Estimated)
OptionableOptionable

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

Is AMAG Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating and 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMAG Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMAG, but not buy additional shares or sell existing shares.
View analyst ratings for AMAG Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AMAG Pharmaceuticals?

Wall Street analysts have given AMAG Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AMAG Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for AMAG Pharmaceuticals
.

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its earnings results on Friday, November, 6th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.24. The specialty pharmaceutical company had revenue of $93.11 million for the quarter, compared to analyst estimates of $61.77 million. AMAG Pharmaceuticals had a negative net margin of 74.93% and a negative return on equity of 16.92%.
View AMAG Pharmaceuticals' earnings history
.

What price target have analysts set for AMAG?

7 brokers have issued 12-month target prices for AMAG Pharmaceuticals' shares. Their forecasts range from $7.00 to $13.75. On average, they expect AMAG Pharmaceuticals' share price to reach $9.91 in the next twelve months. This suggests that the stock has a possible downside of 27.9%.
View analysts' price targets for AMAG Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of AMAG Pharmaceuticals' key competitors?

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Palatin Technologies (PTN), Bausch Health Companies (BHC), Broadcom (AVGO), (CELG), Gilead Sciences (GILD), Netflix (NFLX), Energy Transfer (ET), Ford Motor (F), Tesla (TSLA) and NVIDIA (NVDA).

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the following people:
  • Dr. William K. Heiden, CEO, Pres & Director (Age 60, Pay $1.28M)
  • Mr. Anthony Casciano, Exec. VP & COO (Age 43, Pay $625.19k)
  • Mr. Joseph D. Vittiglio, Exec. VP, Gen. Counsel, Chief Bus. Officer & Corp. Sec. (Age 48, Pay $672.28k)
  • Mr. Scott D. Myers M.B.A., Pres, CEO & Director (Age 54)
  • Mr. Brian Piekos, Exec. VP & CFO (Age 46)
  • Ms. Linda S. Lennox, VP of Investor Relations & Corp. Communications
  • Mr. Amit Verma, VP of Marketing
  • Ms. Kelly Schick, Sr. VP, Chief HR Officer & Head of Corp. Engagement
  • Dr. Laura Williams M.D., M.P.H., Sr. VP of Clinical Devel.
  • Mr. Peter Bawin, Sr. VP & GM of Cord Blood Registry

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $13.75.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $477.47 million and generates $327.75 million in revenue each year. The specialty pharmaceutical company earns $-466,460,000.00 in net income (profit) each year or ($6.88) on an earnings per share basis. AMAG Pharmaceuticals employs 440 workers across the globe.

What is AMAG Pharmaceuticals' official website?

The official website for AMAG Pharmaceuticals is www.amagpharma.com.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.